1 The aims of the study were to assess the contribution of prostaglandins and nitric oxide (NO) to the effects of endothelin (ETs) and sarafotoxin 6c (SX6c) in perfused rat lungs. This was carried out by using indomethacin, a cyclo-oxygenase inhibitor and NG-nitro-L-arginine (L-NOARG), a NO synthase inhibitor. Responses were studied under basal perfusion conditions and in other experiments after the elevation of vascular tone with the thromboxane-mimetic, U46619. The sub-types of ET receptors involved were characterized by use of ET receptor antagonists and cross-tachyphylaxis. 2 Pulmonary perfusion pressure (PPP), lung weight and pulmonary inflation pressure (PIP), were continuously recorded. Although L-NOARG (100 gM) did not alter basal parameters it markedly augmented the vasoconstriction and lung weight increases induced by ET-1 (50-400 pmol) or SX6C (25-200 pmol) while vasoconstrictor responses to phenylephrine were not affected by L-NOARG. 3 L-NOARG markedly potentiated the bronchoconstriction induced by ET-1 or SX6C whereas it had no effect on responses to carbachol. 4 When vascular tone was elevated, low doses (1.25-40 pmol) of ET-1, ET-3 and SX6C produced falls in PPP. The vasodilator potencies were SX6C> ET-1 = ET-3. The ETA receptor antagonist, BQ123, did not affect these depressor responses, whereas the mixed ETA/ETB antagonist, bosentan, blocked them. 5 Indomethacin (10 ,M) partially inhibited vasodilator response to ET-1, whereas it had no effect on SX6C-induced vasodilatation. 6 L-NOARG plus indomethacin completely blocked ET-1 induced vasodilatation, whereas responses to SX6C were blocked by L-NOARG alone. 7 Repeated injections of submaximal doses of ET-1 or SX6C caused tachyphylaxis to vasodilator responses. Subsequent injections of SX6C -or ET-1 did not elicit depressor responses showing cross tachyphylaxis had occurred. 8 These findings indicate that under basal conditions the pulmonary vasoconstrictor, lung weight and bronchoconstrictor responses to ET-1 and SX6C are attenuated by evoked release of nitric oxide (NO). When vascular tone was elevated, lower doses of ETs and SX6C produced vasodilatation. These vasodilator responses are indirect, those to SX6C being mediated via NO production, whereas those to ET-1 involve both NO and prostanoid(s). Tachyphylaxis and ET antagonist experiments indicate that the same receptor subtype is involved in mediating the vasodilatation and that this is of the ETB type located on the endothelium. However the post-receptor vasodilator events triggered by ET-1 or SX6C appear to be different.
Introduction
There is increasing evidence that endothelins may have a role to play in pulmonary disease (see Barnes, 1994; Hay & Goldie, 1995) . We (Lal et al., 1995a) and others (Rodman et al., 1992; Bonvallet et al., 1993; MacLean et al., 1994) have provided pharmacological evidence that the pulmonary vasoconstrictor actions of the endothelins in the rat lung are mediated by ETA and ETB receptor subtypes and that ETA receptors are located primarily on the venous side of the pulmonary circulation while the ETB receptors mediating vasoconstriction are on the arterial side. Stimulation of venous ETA receptors leads to a rise in capillary perfusion pressure and the development of hydrostatic oedema (Rodman et al., 1992; Ercan et al., 1993; et al., 1995a) .
ETB receptors were originally considered as receptors mediating vasodilatation linked to nitric oxide production (Warner et al., 1989) . However, subsequently it was shown that ETB receptors were also involved in smooth muscle contraction (Moriland et al., 1992) . Thus ETB receptors have been subdivided into ETBI (located on the endothelium and med-Author for correspondence. iating vasodilatation) and ETB2 (located on the vascular smooth muscle and inducing contraction) (Douglas et al., 1994) . Sokolovsky et al. (1992) also reported that there appeared to be two subtypes of ETB receptors i.e. the 'super high affinity', ETBI receptors and the 'high affinity', ETB2 receptors. It was suggested that the super high sites showing binding affinity in the picomolar range are related to the vasodilatation property of endothelins whereas the high affinity sites with binding affinity in the nanomolar range participate in the vasoconstrictor actions.
In view of these observations it would be expected that if there were any ETBi receptors in the pulmonary vasculature they should induce relaxation of the pulmonary circulation. However, in our previous experiments (Lal et al., 1995b) examining the effects of ETs on the rat isolated lung we were unable to demonstrate any vasodilator actions, possibly because the pulmonary vessels were already maximally dilated. The present experiments were carried out to examine the effects of endothelins and the ETB agonist, sarafotoxin 6c (SX6C), in more detail using preparations in which the perfusion pressure was elevated by the infusion of the thromboxane analogue, U46619 (Coleman et al., 1981) . For comparison the effects of phenylephrine and the endothelium-British Journal of Pharmacology (1996 Pharmacology ( ) 118, 1931 Pharmacology ( -1938 dependent and endothelium-independent vasodilator agents, carbachol and sodium nitroprusside, were used. Preliminary findings of these studies have been presented to the British Pharmacological Society (Lal et al., 1995c) .
Methods

Isolated ventilated perfused lung preparation
Lungs were isolated and perfused as described previously (Lal et al., 1994) . Male Wistar rats were anaesthetized with an intraperitoneal injection of Sagatal, 60 mg kg-' body weight. Heparin (500 i.u.) was injected via the tail vein, 5 min later the chest wall was opened. A small cut was made in the right ventricular free wall and the pulmonary artery cannulated with a stainless steel cannula (external diameter = 1.5 mm, internal diameter = 1 mm) via the right ventricle. The left atrium was cut and the major part of the ventricles removed to allow free efflux of perfusate. The trachea was cannulated and thereafter the lungs were isolated and perfused via the pulmonary artery at a constant flow of 5 ml min-' with Krebs solution of fola 40-ET-1 lowing composition (mM): KCl 4.7, KH2PO4 1.2, CaC12 1.25, MgSO4 1.2, NaCl 118, NaHCO3 25, glucose 11.1 (gassed with 95% 02 and 5% C02). Pulmonary arterial perfusion pressure (PPP) was recorded via a side arm on the arterial cannula. Lungs were ventilated via the trachea with room air (stroke volume I ml, 28 strokes min-', no positive end expiratory pressure). Pulmonary inflation pressure (PIP) was measured via the tracheal cannula. Lungs were suspended from an isometric transducer to record changes in lung weight. All parameters were recorded on a multichannel recorder (Grass model 7D polygraph). Lungs were allowed to stabilize for 30 min before drug administration. Drugs were administered as bolus doses (10-100 ,l) or infusions (100 jIl min-') via the pulmonary artery.
Elevation of basal PPP with U46619
In a series of experiments basal PPP was elevated by infusion of the thromboxane-mimetic, U46619 (40-80 nM), commencing 20 min after the initial stabilisation period. Ten minutes later bolus injections of agonists were administered at 7-10 min intervals. Effects of inhibitors and receptor antagonists Indomethacin (10 giM) and/or N0-nitro-L-arginine (100 gM) were included in the perfusate for 30 min before agonist injection and were present for the rest of the experiment. Receptor antagonists were included in the perfusate for 20 min before bolus injections of the appropriate agonist were given. The selectivity of inhibitors and receptor antagonists was studied by use of phenylephrine, carbachol and sodium nitroprusside.
Drugs and chemicals
BQ123, (cyclo[D-Asp-L-Pro-D-Val-L-Leu-D-Trp]) was supplied by Dr A.G. Roach, Rhone Poulenc Rorer, Dagenham. Bosentan (4-tert-butyl-N-[6-(2-hydroxy-ethoxy)-5-(2-methoxyphenoxy)-2,2'-bipyrimidin-4-yl]-benzenesulphonamide sodium salt) was provided by Hoffmann-La Roche Ltd (Basel, Switzerland). Endothelin-1 and endothelin-3 were obtained from Novabiochem (UK) Ltd. Sarafotoxin 6c was from Peninsula Laboratories. Indomethacin, L-phenylephrine hydro-chloride,9,1 l-dideoxy-1 1,9a-epoxy-methanoprostaglandin F2q (U46619), sodium nitroprusside, N0-nitro-L-arginine and NG-nitro-D-arginine were from Sigma, Poole, Dorset. U46619 was dissolved in 95% ethanol and stored at -800C; working dilutions were made in isotonic saline. Stock solutions of all other drugs were prepared in isotonic saline and stored at -200C.
Statistical analyses
Increases in PPP, PIP and lung weight induced by bolus injections of phenylephrine, carbachol, endothelin-1 and sarafotoxin 6c are expressed relative to the value prior to the addition of each dose. Pulmonary vasodilator responses are expressed as % decreases of the U46619-induced increase in pressure. When lung weight measurement was needed for comparative purposes, weight gain was calculated 7 min after giving the maximum dose of agonist (Lal et al., 1995a) . Data are expressed as mean + standard error of the mean (s.e.mean), in many cases the error bars fall within the symbols and are therefore not shown. ANOVA followed by Dunnett's test for multiple comparisons or Student's (unpaired) t test for comparison of individual means. Probability values of P<0.05 were considered significant.
Results
(a) Effects of nitro-L-arginine (L-NOARG) on responses to ET-I and sarafotoxin 6c (SX6C) Inclusion of L-NOARG (100 1iM) in the perfusate for 30 min did not affect basal PPP, measured immediately prior to L-NOARG addition (5.4 + 0.6 mmHg, n = 7 in control vs. 5.4 + 0.5, n = 9). In addition there were no effects on bronchial tone (basal PIP 4.15 + 0.2 mmHg, n = 7 in control vs. 5.24+0.3 mmHg, n=9) or lung weight (2.85+0.14 g, n=7 in control vs. 2.84+ 0.12 g, n = 9). Figure 1 shows that PPP, lung weight and PIP responses to ET-1 50-400 pmol (b left panel) or, SX6C 25-200 pmol (b right panel) in the presence of L-NOARG were markedly potentiated when compared to control ET-1 50-400 pmol (a left panel) or SX6C 25-200 pmol (a right panel) respectively in the absence of L-NOARG. Furthermore, L-NOARG produced more marked potentiations in the responses to SX6C as compared to . The quantitative data is expressed in Figure 2 . From Figure 2a it can be seen that L-NOARG potentiated PPP increases in responses to ET-1 100-400 pmol (P< 0.001, n = 4), similarly, SX6C (50-200 pmol)-mediated increases in PPP were also significantly augmented (P<0.001, Each point represents mean+s.e.mean, n=4-13 experiments. **P<0.01; ***P<0.001 ANOVA followed by Dunnett's test. n = 5). The maximum constrictor response to SX6C was also increased in the presence of L-NOARG. Figure 2b illustrates that in the presence of L-NOARG lung weight increases caused by ET-1 and SX6C were also significantly potentiated. In contrast to the potentiation of responses to ET-1 and SX6C, it was of interest to note that L-NOARG did not affect the increases in PPP induced by the cx-adrenoceptor agonist, phenylephrine (3.12-50 nmol) (ED50 4 + 0.7, n =5 in controls vs. 5.4+ 1.7, n = 3) at any dose.
The increases in PIP in response to ET-1 were significantly augmented in the presence of L-NOARG (ED50 242 + 33 pmol, n = 7 in control vs. 132 + 5 pmol, n = 4; P < 0.05). Similarly, the SX6C-induced increases in PIP were also significantly potentiated (ED50 85 + 6 pmol, n = 13 in control vs. 48 + 5 pmol, n = 5; P<0.01) ( Figure 2c ). The apparent reduction in response to the highest doses of SX6C on each curve is a consequence of expressing each increase relative to the PIP measured immediately prior to injection. It was necessary to include these points to establish clearly that maximal responses had been achieved.
The presence of L-NOARG did not alter the bronchoconstrictor responses to carbachol (ED50 4.25 + 0.4 nmol, n = 7 in controls vs. 4+0.3 nmol, n=4) at any dose. 4HLltn a f n rat Iunuv (b) Effects of ETs and SX6C in lungs i tone is increased by U46619 Infusion of U46619 (80 nM) into the pulmc duced an increase in PPP of 9 + 0.5 mmHg or of 5 +0.5 mmHg (n= 16). Under these con jections of ET-1 (2.5-40 pmol), ET-3 (2. SX6C (1.25-40 pmol) all produced dose-d PPP (Figure 3 ). The vasodilator potencies 3.6+0.6 pmol, n= 5) and ET-3 (ED50 3.9+ were similar. However, SX6C (ED50 2.2+± P <0.05) was significantly more potent than (Figure 3 ), although the difference was small (c) Effect of inhibitors and ET receptor vasodilator responses to ET-J and SX6C L-NOARG, D-NOARG and indomethacin ET-l and SX6C responses in the absence presence of the nitric oxide synthase inhil 0-
where vascular ( Figure 4b ). L-NOARG (100 gM) had no effect on basal PPP. However, it augmented the vasoconstrictor action of U46619. Therefore a lower concentration of U46619 was used in order :nary artery proto elevate the PPP by a similar amount to that seen in the ver the basal PPP earlier experiments (approximately 9 mmHg). In this series of editions bolus inexperiments (40 nM) U46619 produced an increase in PPP of 5 -40 pmol) and 8.5 + 0.8 mmHg, n = 8. Figure 4b ( in the presence of L-NOARG (100 giM). The highest dose of SX6C (20 pmol) now produced an increase in PPP (Figure 4b antagonists on right). Accumulated results from a series of experiments are shown in Figure 5 . D-NOARG did not affect the response to any of the agonists ET-1 (ED50 3.6 + 0.6 pmol, n = 5 in control Figure 4 shows vs. 3.2 + 1.2 pmol, n = 4) or SX6C (ED50 2.2 + 0.14 pmol, n = 7 (Figure 4a ) and in control vs. 2.3 + 0.6 pmol, n = 4). Perfusion of L-NOARG )itor, L-NOARG (100 gM) had no effect on vasodilatation produced by the NO donor, sodium nitroprusside (SNP), 10-1000 pmol (data not shown).
In U46619-preconstricted preparations the inclusion of the cyclo-oxygenase inhibitor, indomethacin (10 gM), tended to reduce the vasodilator response to ET-1 (2.5-20 pmol) but this was only significant at the 5 pmol dose (Figure 5a ). However, the ED50 vasodilator value for ET-1 was significantly increased from 3.6 + 0.6 pmol, n =5 in controls to 9 + 3.4 pmol, n = 3 (P< 0.05). In a different set of experiments, perfusion of indomethacin (10 gM) and L-NOARG (100 ,uM)
in combination completely abolished the vasodilator response to ET-1. ET-1 (5-20 pmol) now produced marked rises in PPP (Figure 5a ).
The combination of inhibitors was not tried in the case of SX6C as L-NOARG completely abolished the vasodilator re-|~~~s ponses to SX6C (see above), whereas indomethacin (10 SUm) 20 50 had no effect (ED50 2.2 + 0.14 pmol, n = 7 in control vs.
1.7 + 0.3 pmol, n = 4) ( Figure Sb) . more detail. In these experiments the infusion of U46619 (80 nM) produced an increase in PPP of 9 + 0.6 mmHg, n = 6. The effects of repeated injection of low doses of ET-1 or SX6C (20 pmol each) are shown in Figure 6 . As shown, the dilator responses to ET-1 given at 5-7 min intervals showed a marked tachyphylaxis, the fifth dose of ET-1 actually produced vasoconstriction rather than vasodilatation. When SX6C was given after ET-1 it also produced dose-dependent increases in PPP (Figure 6a) . Similarly, serial doses of SX6C caused marked depressor responses which decreased in magnitude with repeated injections; as can be seen, the sixth injection actually produced a vasoconstriction. Subsequent injection of ET-1 then caused dose-dependent increases in PPP (Figure 6b ).
Discussion
In this lung model the pulmonary perfusion pressure was low.
To determine if constant release of NO is responsible for this, the NO synthase inhibitor L-NOARG was studied at a concentration reported to block constitutive NOS (Moore et al., 1990) . L-NOARG had no effect on basal PPP suggesting that NO is not a major factor contributing to the low vascular tone. This was confirmed as L-NOARG did not potentiate the vasoconstrictor responses to phenylephrine, whereas in other vascular tissues where basal production of NO occurs, phe-/ ** nylephrine responses are potentiated after NO synthase inhibition (Frew et al., 1993) .
ET-1 and SX6C-induced pulmonary vascular and bronchial actions were studied under basal conditions and in the presence of L-NOARG. L-NOARG markedly augmented the vasoconstrictor responses to ET-1 and SX6C. A possible explanation of this potentiation is that ET-1 and SX6C release NO via activation of endothelial ETB receptors (Douglas et al., l 1994) . Inhibition by L-NOARG would then potentiate vaso-5 10 20 50 constriction mediated via ETA and ETB receptors on the vas-Dose (pmol) cular smooth muscle. This is supported by the observation that in rat isolated pulmonary arteries, potentiation of ET-1induced contractions in the presence of a NOS inhibitor were hre pulmonary vascular responses to reversed after removal of the endothelium ( elevates cyclic AMP thus offsetting the constriction mediated via the other subtype (Eguchi et al., 1993) . Our previous finding that a low dose of BQ123 potentiated pulmonary vact on the vasodilator responses to soconstrictor responses to ET-1 whilst higher doses blocked ol ED50 3.6 + 0.6 (n= 5) vs. them would support this hypothesis (Lal et al., 1995b) . L-NOARG also potentiated lung weight increases in response to ET-1 or SX6C. These increases are probably secie mixed ETA/ETB receptor anondary to the enhanced vasoconstrictor responses. The idied on pulmonary vasodilator relationship between pulmonary vasoconstriction and pul-C. Perfusion of bosentan (5 gM) monary oedema formation (lung weight increase) has been (5.1 + 0.5 mmHg, n = 8). The in-explored (Lal et al., 1995a) . The primary conclusion was that iroduced an increase in PPP of the venoconstrictor action of these substances increases lung ;entan abolished (P<0.001) the weight by producing a hydrostatic oedema. In this earlier study in response to it was also shown that SX6C acted primarily on the arterial pmol). Bosentan had no effect on side of the circulation whereas the action of ET-1 was pre-'P (100 pmol of SNP in the pre-dominantly venous. However, in the present experiments Lfall in PPP of 27% + 2 in control NOARG potentiated lung weight increases to SX6C more st preparations).
than to ET-1. This further supports the suggestion that SX6C is more potent in releasing NO than ET-1 and indicates that I and SX6C
activation of ETB receptors on the venous endothelium by SX6C in normal lungs must be sufficient to mask the venoves to the vasodilator effects of constrictor responses (and hence increases in lung weight) instructed, it was noted that re-which are only revealed after inhibition of NO synthesis. This which produced a maximum va-concept is supported by the work of Zellers et al. (1994) than that from pulmonary arteries. The second possibility is that NO causes preservation of endothelial barrier function to prevent extravasation (Zi-Qiang et al., 1994) .
ET-1 and SX6C-induced bronchoconstriction were also potentiated by L-NOARG suggesting that evoked release of NO was inhibiting their bronchial constrictor actions. Both lung endothelial and epithelial cells can release NO (Xue et al., 1994) and although both sources would be inhibited by L-NOARG, the source of NO in these responses is probably the airway epithelium rather than vascular endothelium. Indeed (Filep et al., 1993) have implicated epithelium-derived NO in ET-1-induced relaxation of guinea-pig tracheal smooth muscle. The bronchoconstrictor effects of SX6C in the presence of L-NOARG were potentiated to a greater extent than the effects of ET-1, again indicating that SX6C is more potent in releasing NO. L-NOARG had no effect on bronchoconstrictor responses to carbachol suggesting that it did not stimulate NO production.
In U46619 pre-constricted preparations, very low doses of ET-1, ET-3 and SX6C produced dose-dependent falls in PPP. ET-1 was equipotent with ET-3 whereas, the highly selective ETB receptor agonist, SX6C (Williams et al., 1991) was significantly more potent. Furthermore, a ETA receptor antagonist, BQ123, did not block the vasodilator response to ET-1, whereas, a mixed ETA/ETB receptor antagonist, bosentan, completely abolished the dilator responses to ET-1 and SX6C, indicating a role for ETB receptors in these responses. Bosentan did not affect vasodilatation caused by sodium nitroprusside, suggesting that it is having a selective action. These observations are in agreement with those of Eddahibi et al. (1995) .
In U46619 pre-contracted preparations, indomethacin did not affect SX6C-induced vasodilatation but it did reduce the vasodilator effects of ET-1 as shown by the increase in the ED50. This suggests that ET-1-induced pulmonary vasodilatation is partially mediated by the release of vasodilator prostanoids. This is further supported by the fact that in the presence of L-NOARG there was an indomethacin-sensitive ET-1-mediated vasodilator response at the lowest dose used. Vasodilator actions of ETs have also been shown to be partially inhibited by indomethacin in vivo in cats (Ekelund et al., 1994) , while DeNucci et al. (1988) have shown ET-1 stimulated prostacyclin synthesis in rat lungs.
The possible role of NO in ET-l-and SX6C-induced vasodilatation was evaluated by use of L-NOARG. L-NOARG potentiated the pressor responses to U46619, suggesting that U46619 also evoked endogenous production of NO in the rat pulmonary circulation. Similar findings have been reported in lungs from neonatal pigs (Pinheiro & Malik, 1993) . Therefore, in lungs treated with L-NOARG, a lower concentration of U46619 had to be used in order to elevate the PPP to a similar level seen in the absence of L-NOARG.
In the present experiments L-NOARG blocked the vasodilatation induced by the higher doses of ET-1. However, at the lowest dose of ET-1, L-NOARG revealed a significant vasodilator response which was inhibited by indomethacin. This could be explained by the suggestion of Keen et al. (1990) who showed the feed-back control of vasodilator prostanoid by nitric oxide. D-NOARG was without effect. Vasodilator responses to ET-1 were abolished by the combination of indomethacin and L-NOARG, indicating that the vasodilator actions of low doses of ET-1 in the rat pulmonary circulation are mediated by prostanoid release while higher doses cause release of both prostanoids and NO. Similar findings have been reported in porcine pulmonary blood vessels (Zellers et al., 1994) , and perfused lungs (Pinheiro & Malik, 1993) . As L-NOARG alone completely abolished the vasodilatation caused by SX6C, whereas D-NOARG did not, this indicates mediation via NO production. However, these findings are at variance with the observations of Eddahibi et al. (1993) . This may be due to their use of a different NOS inhibitor, NGmonomethyl-L-arginine (L-NMMA) which has been reported to inhibit selectively basal release of NO without affecting the agonist-evoked release (Frew et al., 1993) . In support of this suggestion Namiki et al. (1992) have shown that L-NOARG blocked the ET-1-induced relaxation of porcine isolated pulmonary arteries. The selectivity of action of L-NOARG in our work was demonstrated by its lack of any effect on the vasodilator actions of sodium nitroprusside.
Repeated injections of a single dose of ET-1 or SX6C (20 pmol) caused a rapid loss of pulmonary vasodilator responses. Other investigators have reported a similar phenomenon when measuring vasodepressor responses in cats and rats (LeMonnier DeGouville et al., 1990; Lippton et al., 1993; Ekelund et al., 1994) (Kitazono et al., 1995) which are mediated by ETB receptors. In ET-1-desensitized lungs, further injections of very low doses of SX6C also failed to cause vasodilatation, instead they produced dose-dependent vasoconstriction. Similarly in lungs desensitized with SX6C, injections of low doses of ET-1 produced dose-dependent vasoconstriction. This suggests the development of cross-tachyphylaxis to the vasodilator actions of ET-1 and SX6C. Several possibilities could explain this phenomenon. First, ET-1 and SX6C may stimulate a single type of receptor that becomes rapidly refractory to activation by these peptides. Alternatively, ET-1 and SX6C could bind to distinct receptor sites which share at least one common point in the second messenger system. This shared portion of the reaction chain may then become impaired or refractory, after repeated stimulation of the receptors.
In summary, the present study has shown that under basal conditions evoked release of NO attenuates the pulmonary vasoconstrictor and bronchoconstrictor actions of ET-1 and SX6C. When vascular tone was elevated, lower doses of ET-1, ET-3 and SX6C produced vasodilatation probably via ETB receptors located on the endothelial cells. In addition we have also shown that in this model, repeated injections of ET-1 or SX6C produced tachyphylaxis to the vasodilator responses. The rapid development of tachyphylaxis to the vasodilator response may have important implications in the pathogenesis of pulmonary hypertension where pulmonary ET-1 production is enhanced (Stewart et al., 1991) as the constrictor effects of ET-1 would not be opposed by its dilator actions. We have also provided evidence that the vasodilator responses to ET-1 are mediated by the release of both NO and prostanoids, whereas the vasodilator effects of SX6C are mediated solely by NO production.
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